GEHC
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of pa...
GE HealthCare Technologies Inc. (GEHC) 投资分析
主要经营地
美国/全球
详细的生意模式
医疗影像设备（MRI/CT/超声等）+监护+诊断试剂/药物诊断+软件/AI；通过装机销售+服务/耗材/软件订阅获取持续收入。
护城河
庞大装机基数带来的服务与升级粘性；监管认证壁垒；与医院流程深度绑定形成高切换成本。
估值水平
FCF/EV 3.9%；EV/EBITDA 11.1x；PE 17.9x
EV/Market Cap
1.17x
网络观点
✅看多：作者认为市场把它误当“周期设备商”，而实际正向软件/AI与诊断耗材的经常性收入转型；估值约16x对比同业29–37x存在重定价空间。
AI的观点
我的判断：在大盘里算“质量‑估值错配”较明显的候选。✅若经常性收入占比持续上升、利润率改善，估值有望向同业靠拢；❌风险在于影像设备更新周期与医院资本开支放缓。建议对照年报/Investor Day核对：经常性收入口径、研发投入与资本回报。
作者简介
社媒 @thegresearch；专业投资者否；顶级作者否；13F持仓否；历史总回报0.9% (10 trades)
$GEHC: An Earnings Growth Masterclass (No Paywall)
GE HealthCare Technologies (NASDAQ: GEHC) is a high-conviction long idea. After its spin-off from General Electric, GEHC is transforming its business model from cyclical equipment sales to high-margin recurring revenue from software, AI, and diagnostics. The stock is considered mispriced, trading at a significant discount to medtech peers. Key catalysts include a new product cycle, margin expansion, and capital returns. A near-term price target of $110 and a long-term target of $200 are suggested, implying a 20.11% annualized IRR.